The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Genetic mechanisms driving thrombocytopenia in MF patients
In this video, Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, shares some insights into a study which investigated genetic mechanisms driving thrombocytopenia in patients with myelofibrosis (MF). Dr Kuykendall first explains the methodology used in this study, and then goes on to discuss some results, which suggested that disease-related thrombocytopenia was associated with three unique prognostic factors: presence of a TP53 mutation, presence of an SRSF2 mutation, and low serum albumin. To conclude, Dr Kuykendall comments on how the identification of these genetic factors may be used to improve prognosis and patient outcome. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research fees – Morphosys, GSK
Honoraria – Incyte
